Public Release Summary on the evaluation of the new active cyflumetofen in the product Danisaraba Miticide

This consultation closed on 11 January 2022.
Consultation period: 
14 December 2021 to 11 January 2022

The Australian Pesticides and Veterinary Medicines Authority (APVMA) is considering an application for registration of the product Danisaraba Miticide containing 200 g/L of the approved active constituent cyflumetofen, as a suspension concentrate (SC) formulation. The product is intended for the control of various species of mites in pome fruits, almonds, citrus, grapes, fruiting vegetables, strawberries and ornamentals.  

We invite comment from 14 December 2021 to 11 January 2022 on whether approval of the active constituent and registration of the product should be granted.

The APVMA is able to consider comments relating to the legislative grounds, including:

  • occupational health and safety
  • public health
  • chemistry and manufacture
  • residues in food
  • environmental safety
  • trade
  • efficacy and target crop safety.

Download the Public Release Summary on the evaluation of Danisaraba Miticide.

For more information see page 34, APVMA Gazette No. 25, 14 December 2021

Please note: Submissions will be published on the APVMA’s website, unless you have asked for the submission to remain confidential (see public submission coversheet).

Please lodge your submission with a public submission coversheet, which provides options for how your submission will be published.

Note that all APVMA documents are subject to the access provisions of the Freedom of Information Act 1982 and may be required to be released under that Act should a request for access be made.

Please send your written submission by email, post or fax to:

Case Management and Administration Unit
Australian Pesticides and Veterinary Medicines Authority
GPO Box 3262
Sydney NSW 2001

Phone: +61 2 6770 2300
Email: enquiries@apvma.gov.au

Your feedback will be submitted to the APVMA anonymously. If you require a response, please contact us.